Therefore neutralizing anti-TNF-α biotherapeutics such as golimumab (Simponi), infliximab (Remicade), adalimumab (Humira), certolizumab (Cimzia), or etanercept (Enbrel) are popular steroid-sparing agents in the treatment of TNF-α–mediated inflammation in many rheumatologic disorders, including chronic plaque psoriasis, juvenile idiopathic arthritis, ulcerative colitis, and Crohn's disease for many years.2 The gene discussed is TNF; the disease is ulcerative colitis.